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Abstract 
Objectives: Although people with amnestic mild cognitive impairment (aMCI) benefit from cere-
brolysin treatment, some still develop dementia. The aim of the current study was to identify most 
informative clinical assessment tests to predict the therapy efficacy in aMCI subjects treated with 
cerebrolysin. Methods: We studied patients with amnestic mild cognitive impairment (aMCI; n = 
53) who had regular neurocognitive and clinical psychiatric assessments and were treated with 
cerebrolysin i.v. infusions 20 × 30 ml twice a year over three years period. Data were analyzed us-
ing non-parametric statistics, cluster and linear discriminant analyses. Results: Combined ma-
thematical modeling enabled to predict cognitive decline from aMCI to dementia in the cerebroly-
sin-treated patients based on their initial neurocognitive assessment scores. We identified a “de-
mentia risk group” with fast cognitive decline (i.e. low efficacy of the treatment). Lower baseline 
scores in the Mattis Dementia Rating Scale Memory subtest, Mini-Mental State Examination (MMSE), 
10 word list immediate recall, and Frontal Assessment Battery tests when accompanied by higher 
depression score (Hamilton Depression Rating Scale) suggest poor prognosis for aMCI patients 
treated with cerebrolysin. Changes in scores on the MMSE, Boston naming test, Digit span forward, 
and Wechsler scale subtest “Categorical associations” during the treatment course are more cha-
racteristic for patients who convert to dementia than their initial scores. Conclusions: aMCI sub-
jects treated with cerebrolysin with lower baseline cognitive functioning and subclinical depres-
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sion have poor prognosis in terms of converting to dementia. Changes in the MMSE, Boston naming 
test, Digit span forward, and Wechsler scale subtest “Categorical associations” scores during the 
treatment course are more informative to identify patients who will develop dementia than their 
initial scores. 
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1. Introduction 
A number of population studies have consistently reported that people with mild cognitive impairment (MCI) 
frequently develop Alzheimer’s disease (AD) dementia [1]-[5]. The MCI syndrome, at least its amnestic type 
(aMCI), is now considered to represent an early (pre-clinical) stage of AD [6]. Clinical, psychopathological and 
neurocognitive studies have attempted to define a set of clinical signs which can serve as predictors of conver-
sion to dementia in MCI subjects, and these include a set of tests used in the present study [7]. 
Despite numerous USA and European multi-center studies on identifying biological and clinical predictors of 
dementia conversion in MCI patients, little is known about how to detect MCI subjects at high risk to develop 
AD [8]. One way of addressing this is to use baseline and repeated screening data from long-term longitudinal 
studies on MCI. One such study is published by Gavrilova et al. [9]. This comparative controlled multi-center 
clinical study followed MCI subjects with no prominent vascular disorders who were on long-term therapy with 
cerebrolysin (regular four-week courses, twice a year) with an aim to prevent further cognitive decline and con-
version to AD. In general, cerebrolysin demonstrated its high efficacy in prevention of cognitive decline and 
dementia development within three years in groups of 37 [10] and 55 [9] MCI patients. 
The present study is a continuation of our work with further analysis of data obtained previously [9]. The 
main aim is to identify the most informative clinical attributes (e.g. clinical tests/scores) as predictors of MCI 
cognitive decline and whether they can distinguish “dementia risk group” among MCI patients enrolled in 
treatment trials. Since the frequency of ApoEε4 allele is both significantly higher in AD [11] and MCI subjects 
at high risk to convert to AD [9] [12], the present study also includes APOE genotyping data for all the studied 
MCI patients. 
2. Material and Methods 
2.1. Subjects 
The study was approved by the Ethical Committee of the Mental Health Research Center (MHRC) of RAMS 
and was carried out in three Research Centers: Department of Alzheimer’s Disease and Associated Disorders of 
MHRC RAMS (Moscow), Department of Mental and Neurological Diseases at the Military Medical Academy, 
St.-Petersburg, and Department of Neurology, Neurosurgery, and Psychiatry, Nizhny Novgorod State Medical 
Academy, Nizhny Novgorod, Russia. 53 patients in total were enrolled in the study, and assessed using an iden-
tical clinical battery. All participants signed an Informed Consent Form. Their median age was 68 years (53 - 83 
years), 13 were males and 25 had ApoEε4 allele. Inclusion and exclusion criteria are listed in Table 1. 
All subjects met the Petersen et al. [1] [13] criteria for aMCI (Memory problems, preferably corroborated by 
an informant; Impaired memory function for age and education; Preserved general cognitive function; Intact 
activities of daily living; Absence of dementia) and were regularly treated with cerebrolysin (Ebewe Pharma, 
Austria), a total number of 20 × 30 ml intravenous infusions, twice a year over a three year period (2007-2010). 
All participants were clinically assessed with the following psychometric battery: Global Deterioration Scale 
(GDS) [14]; Clinical Dementia Rating (CDR) [15]; Hamilton Depression Rating Scale (HDRS) [16]; Modified 
Hachinski Ischemic Scale (MIS) [17]; Mini-Mental State Examination (MMSE) [18]; Mattis Dementia Rating 
Scale (MDRS) with subtests, incl. Reciprocal coordination, Graphomotor, Similarities, Memory [19]; Wechsler 
Scale Subtests (WAIS), incl. Acoustic associations, Categorical associations, Digit span forward (Repeat spoken  
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Table 1. Inclusion and exclusion criteria for participants of the study.                                               
Inclusion criteria Exclusion criteria 
55 - 85 years people from both genders Dementia diagnosis (according to DSM-IV, ICD-10 criteria) 
MMSE > 25/30 
Neurological disorders (e.g. congenital and/or acquired metabolic encephalopathy,  
toxic and drug-induced encephalopathy; Parkinson disease, multi-infarct dementia,  
stroke, epilepsy, infectious diseases, demielinating and inherited neurodegenerative  
disorders, traumatic brain injury) 
Subjective memory complains confirmed by close  
family member Endocrine disorders, including decompensated diabetes 
Objective signs of memory problems Neoplasm 
ADLs not overtly altered HIV infection 
Modified Hachinski Ischemic Scale (MIS) < 4, and  
Hamilton Depression Rating Scale (HDRS) < 18 at  
baseline 
Mental disorders 
3rd stage Global Deterioration Scale (GDS) Alcoholism and/or drug dependence 
0.5 score on Clinical Dementia Rating (CDR) Drug induced or other intoxication 
No clinical diagnosis of dementia Folate or vitamin B12 deficiency 
Signed Informed consent obtained Systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg 
 
list of digits in the same order—forward, Digit span backward; Word List Memory Task (10 word list learning 
and immediate recall; Delayed reproduction of 10 word list) [20]-[22]; Frontal Assessment Batterie (FAB) [23]; 
Clock Drawing Test (CDT) [24]-[26]) and Boston Naming Test (BNT) [27]. 
All participants underwent neuroimaging with magnetic resonance tomography to exclude underlying vascu-
lar pathology. APOE genotyping was done in the Laboratory of Molecular Genetics, MHRC RAMS. Genomic 
DNA was isolated from peripheral blood leukocytes using standard routine protocol [11] and APOE genotype 
determined with PCR [11]. 
2.2. Statistics 
The analysis of data was done using the following statistical tests: 
1. Non-parametric tests included Spearman rank-order correlation coefficients, Pairwise Wilcoxon Rank Sum 
Tests and Mann-Whitney U-test; 
2. Cluster analysis was completed with Clust1 algorithm developed in the MHRC RAMS ([28]) and iterative 
cluster analysis. Clust1 algorithm was used for object clustering of 53 subjects (patients) against 14 attributes 
(i.e. scores in 14 neurocognitive tests after the treatment). Distinctive features of Clust1 algorithm are summa-
rized as follows [28]: a) it uses data in a nominal scale based on number of observations for given value; b) it 
uses quantitative evaluation of an subject by attributes measured by different scales (nominal, ordinal, and ratio 
scale). The quantitative evaluation is calculated as a sum of quantitative measures of data belonging to distinct 
scales (e.g. nominal, ordinal, interval and ratio); c) it uses extensive method—determination of matrix of dis-
tances by analyses of all combinations of data; d) unlike most clustering methods, where using matrix of dis-
tances employs empiric evaluations for assignment of subjects to clusters, the Clust1 method renders the as-
signment of subjects to clusters based only on information structure of the matrix of distances without empiric 
criterions. Several clustering methods exist at present not involving usage of matrix of distances, but they do not 
employ combination of different scales of data; e) clustering by Clust1 algorithm, although not providing any 
model of a system under study, allows visualization of interrelationships between subjects (patients) and attributes 
(testing results, genotyping etc.). 
3. Linear discriminant analysis (LDA). 
LDA involves determination of weight coefficients to test results that are considered, where the value of final 
attribute is calculated for each patient:  
1
N
i i
i=
y = a x∑  
where N—number of test results taken into account, 
ai—weight coefficient for i-th test, 
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xi—numerical value of i-th test result. 
The best distinction between two analyzed groups of participants (for instance, with/without dementia out-
come) by the final attribute is usually established when the source data is normally distributed. 
3. Results 
An extensive database was created over the three year period containing a number of clinical parameters for all 
53 participants, including age, gender, their APOE genotype, HDRS, MIS scores, as well as results of 14 neuro-
cognitive tests (MMSE, FAB, CDT, Acoustic Associations, Categorical Associations, Digit span forward, Digit 
span backward, BNT, 10 word list immediate recall, Delayed word recall 10-Word (DWR), Reciprocal coordi-
nation, Graphomotor, Similarities, MDRS Memory subtest) prior and following their cerebrolysin treatment 
course. Three patients who completed the cerebrolysin treatment were diagnosed with AD. 
3.1. Correlation Analysis of Attributes Database 
In order to identify links between attributes, we performed a correlation analysis. All clinical attributes were 
significantly positively correlated (R from 0.41 to 0.63; p < 0.002), with the exception of HDRS and MDRS si-
milarities subtests, that were negatively correlated (R = −0.4, p = 0.002). None of the attributes (prior or after the 
treatment) was associated with participants’ age. 
3.2. Cluster Analyses of Database 
Due to the high R correlations, we used clustering algorithms to define subgroup of MCI patients who have sim-
ilar neuropsychological results as those patients who were diagnosed with dementia post-treatment. Cluster 
analysis, being applied to classification of subjects (patients) allows objective definition of similar subjects 
comprising homogenous subgroups from the total cohort of patients. 
Clustering using Clust1 algorithm: Clustering was done by attributes, using the results from 14 neurocogni-
tive tests after cerebrolysin treatment. We obtained four clusters using basic and modified Clust1, based on close 
correlations between analyzed attributes. One result was selected in which two clusters (K1, containing 34 pa-
tients, and K2, containing 19 patients) were obtained at the first level of clustering, with K2 containing all three 
MCI patients who converted to dementia. We, thus, refer to K2 as “unfavorable”, or “at dementia risk” in rela-
tion to therapy efficacy, whereas K1 has a “favorable” outcome. 
Participants’ age was similar in both clusters, whereas more women (19/15) were found in the “unfavorable” 
K2 cluster. K2 cluster had worse performance (Mann-Whitney U-test, Bonferroni correction for multiple com-
parisons using strict criteria for significance of differences p < 0.006) on following measures: MMSE, p = 
0.0015; FAB, p = 0.000003; Categorical associations, p = 0.002; 10 word list immediate recall, p = 0.0001; Re-
ciprocal coordination, p = 0.0003; MDRS Memory subtest, p = 0.0004; and BNT, p = 0.006. Testing results for 
representatives of K1 and K2 clusters after the treatment are given in Table 2. 
The attributes with a predictive value for MCI converting to dementia were explored in the data collected 
prior starting the treatment. The attributes (initial results of tests of patients comprising both K1 and K2), which 
differ significantly by Mann-Whitney U-test with Bonferroni’ correction were: FAB, p = 0.0005; 10 word list 
immediate recall, p = 0.002; MDRS Memory subtest, p = 0.006; and at tendency level—HDRS, p = 0.008. 
Definition of informative attributes—features of patients with dementia outcome: For the purpose of defining 
 
Table 2. Results of tests after the treatment in K1 (favorable) and K2 (unfavorable) clusters.                             
Statistics 
Tests 
MMSE FAB Categorical  associations BNT 
10 word list 
immediate recall 
MDRS Memory 
subtest 
Median K1 29 14 17 50 8 23 
Spread of values: 
Minimum K1 - Maximum K1 27 - 30 9 - 15 5 - 20 33 - 55 4 - 10 18 - 25 
Median K2 28 12 14 49 7 22 
Spread of values: 
Minimum K2 - Maximum K2 27 - 30 6 - 15 7 - 18 26 - 53 4 - 8 15 - 23 
MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Batterie; BNT, Boston Naming Test; MDRS, Mattis Dementia Rating Scale. 
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the attributes contributing to distinct treatment outcome, we divided the patient cohort into two subgroups: three 
patients with dementia outcome and other 50 patients who did not convert to dementia (Table 3). All three pa-
tients with dementia outcome were women with ApoEε4 allele and had worse performance on their cognitive 
scores prior treatment, as well as post treatment, compared to other MCI subjects who did not convert to demen-
tia (Table 3). 
Iteration cluster analysis—Spearman distances: For the iteration cluster analysis, we used only the signifi-
cantly different attributes (Table 3) that were also significantly different between K1 and K2 clusters (obtained 
with Clust1). The iteration cluster analysis, done with before the treatment attributes resulted in dendrogram us-
ing “Spearman distances” (which allows identification of three non-overlapping clusters of subjects/patients): 
the first cluster (K1a, 16 patients) contains two patients with dementia outcome, the second K2a (6 patients) 
contains one such patient (these two clusters may be regarded as “unfavorable” and “intermediate”, respectively) 
whereas the third cluster (K3a, 31 patients) does not contain any of the three patients with dementia outcome af-
ter the treatment; hence, it may be considered as the one with favorable treatment outcome. 
k-Means clustering: Clustering of patients by k-means method (where k may be taken equal to three, based 
on the above results) and using Euclidean metric (Euclidean distance) gives three clusters K1b, K2b, K3b, with 
20, 6 and 27 patients, respectively. The composition of these clusters did non-significantly differ from previous 
results; thus K1b contains one patient with dementia outcome and K2b contains two such patients. 
Attributes obtained before, after the treatment, and measured only once (e.g. HDRS, MIS) were compared in 
the obtained clusters by Kruskal-Wallis and Chi-square methods. Similar results as those obtained previously 
were also confirmed with this method. Thus, the significant differences between the HDRS and the MIS scores 
were confirmed, as well as the differences in scores obtained with MMSE, FAB, 10 word list immediate recall, 
and MDRS Memory subtest before and after cerebrolysin treatment. Significant differences in scores in BNT 
and 10 word list delayed recall were observed after the treatment (data not shown). 
The attribute “HDRS scores” significantly influenced the clustering results, because its exclusion from the 
attribute list (Table 3) results in only one cluster formation, consisting of all patients. This provides yet another 
indication of the HDRS importance in classifying our patients: the highest scores in this test were in the cluster 
with “unfavorable” treatment outcome (containing two patients with dementia), whereas the lowest HDRS 
scores in the cluster containing patients with “favorable” outcome (no dementia) only. 
Although the cluster analysis identified favorable and unfavorable outcome groups pre- and post-treatment, 
none of the clustering results led to a clear separation of patients with dementia outcome from those without. 
However, using the applied clustering methods based on scores from clinical tests before the treatment, a risk 
group can be selected, containing MCI subjects who would deteriorate in their cognitive functioning during 
three-year period. Furthermore, the cluster analysis also identified certain neuropsychological attributes asso-
ciated with a worse cognitive outcome, including higher scores high or low scores are individual scores rela-
tively the maximum—peak of frequency distributions in the patient cohort, i.e. values which met with the highest 
frequency in the studied cohort of 53 patients in HDRS and lower scores in MMSE, MDRS “Memory” subtest, 
 
Table 3. Results of comparison (Mann-Whitney U-test) between three patients with dementia outcome and others (50 pa-
tients of cohort) by attributes before the treatment and changes in scores in tests (initial-final).                          
Tests Test scores before the treatment Z Changes in scores Z 
MDRS Memory subtest 2.5a 1.1b 
HDRS 2.0 - 
MMSE 1.7 1.9 
10 Word list immediate recall 1.7 0.9 
BNT 1.6 2.8 
Digit span forward 0.5 2.5 
Categorical associations 0.2 1.9 
aThe first value (the second column in the table) refers to difference between two groups in their resulting tests before the treatment; bThe second val-
ue (the third column in the table)—the difference between these groups in changes of scores, i.e. difference between the numerical values of test 
scores before and after the treatment. Those attributes for which Z > 1.64, i.e. the difference between the groups in these attributes is significant with 
probability of 90%, are given in bold. MDRS, Mattis Dementia Rating Scale; HDRS, Hamilton Depression Rating Scale; MMSE, Mini-Mental State 
Examination; BNT, Boston Naming Test. 
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as well as 10 word list immediate recall and FAB, similar to those observed in MCI subjects with dementia out-
come. 
3.3. Linear Discriminant Analysis 
We applied linear discriminant analysis (LDA) to clinical tests’ scores to test the possibility of dividing the pa-
tients into two groups, patients with (n = 3), and without dementia (n = 50) outcome. Since there are two groups, 
the result of LDA is a mathematical transformation of scorings, representing their linear combination with the 
outcome of one numerical attribute. Since the group of patients with dementia outcome contains only three pa-
tients, the normality validation of the source data distribution for this group is not possible. The LDA was based 
on attributes selected as follows. 
A. Linear separability of patient groups by all testing results as the source data. Values of weight coefficients 
were obtained using scores in 14 tests before the treatment (initial), and changes in testing results (Δ, i.e. after- 
minus before the treatment) (Figure 1(a)). The left column in the histogram is presented by three patients with 
dementia outcome. Thus, the dataset (14 tests) allows clear separation of subjects with dementia from others. 
This suggests that the whole dataset, when the three attributes that were measured once (e.g. AроЕε4 genotype, 
scores in MIS and HDRS) are excluded, is sufficient for this analysis. 
B. Linear separability of patient groups by changes in testing results during the treatment, taking into account 
three “single-measured” tests. The source data included results of three “single-measured” tests and 14 differ-
ences (Δ) between testing results after the treatment and initial testing results (Figure 1(b)). The left column 
 
 
Figure 1. Histograms of patient distribution by the obtained numerical attribute: values of weight coefficients ob-
tained when using as the source data: (a) Before the treatment (initial) and changes in testing results (Δ, i.e. after 
minus before the treatment); (b) Changes (Δ) in testing results during the treatment, taking into account three 
“single-measured” tests; (c) Before the treatment (initial) testing results; (d) Before the treatment (initial) testing 
results with the risk group definition.                                                                 
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represents the three patients with dementia outcome; note, one patient (presented by the second column from left) 
is separated from the rest patients. 
C. Linear separability of two patients’ groups (3 with dementia and others) by attributes before the treatment 
can be used to predict the treatment outcome (see Weight coefficients in Table 4), but in this case LDA is not as 
powerful to separate clearly the two distinct groups of patients (Figure 1(c)). 
D. LDA of source data before the treatment with the risk group definition provides a reasonable differentia-
tion between the groups (Figure 1(d)), the first (“risk group”) contains the three patients with dementia outcome 
and also additional patients (n = 5) with similar attributes. 
The findings from the LDA analysis can be summarized as follows: 
1) When the source data is the set of all 14 twice measured attributes, LDA allows separation of group con-
sisting of three patients with dementia outcome from others (50 patients) (Figure 1(a)). 
2) Changes in tests’ scorings are more informative than scorings before the treatment for separation of pa-
tients with dementia outcome, but LDA enables separation of three patients with dementia outcome from others 
in the both cases (Figure 1(a) and Figure 1(b)). 
3) When using only 14 scorings before the treatment for classification of patients, it is reasonable to separate 
at “risk group” containing, together with patients with dementia outcome, a few patients the most closely located 
to them by attributes (scores), but without dementia outcome (Figure 1(c)). When using all 17 tests (14 scores 
before the treatment and 3 single measured tests) the best results for the separation of groups correspond to risk 
group consisting of eight patients: three patients with dementia outcome plus five without dementia outcome 
(Figure 1(d)). The value of linear combination of scores in 17 tests less than the threshold value (55) corres-
ponds to 37.5% probability of dementia development in individual patient. 
4. Discussion 
The MCI syndrome is heterogeneous and it is still unknown what clinical symptoms and measures predict poor 
outcome (e.g. conversion to dementia) [1] [2] [5] [7] [8] [29]-[32]. Detailed studies of neurocognitive functions  
 
Table 4. Weight coefficients for testing results before the treatment.   
 a Weight coefficient 
Genotyping 3.31 
MIS −0.18 
HDRS −0.44 
MMSE initial −0.13 
FAB initial 0.03 
CDT initial −0.39 
Acoustic Associations initial −0.28 
Categorical Associations initial −0.36 
Digit span forward initial 0.02 
Digit span backward initial 0.96 
BNT initial 0.05 
10 word list immediate recall initial −0.12 
Delayed word recall 10-Word (DWR) initial 0.39 
Reciprocal coordination initial 0.89 
Graphomotor initial 0.07 
Similarities initial −0.75 
MDRS Memory subtest initial 1.70 
MIS, Modified Hachinski Ischemic Scale; MDRS, Mattis Dementia Rating Scale; 
HDRS, Hamilton Depression Rating Scale; MMSE, Mini-Mental State Examination; 
BNT, Boston Naming Test; CDT, Clock Drawing Test; DWR, Delayed word recall; 
FAB, Frontal Assessment Batterie. 
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have identified “episodic memory block” and cued recall to be a prodromal state of AD in MCI subjects [32]- 
[35]. In line with previously described link between AD development and ApoEε4 allele [36], we confirm a 
higher risk of AD conversion in APOEε4 allele aMCI careers, who also have significantly lower scores on a 
number of neurocognitive tests, including MMSE, FAB, CDT and WAIS “Acoustic Association” subscale test, 
despite being treated with cerebrolysin, a neurotropic that targets the size and number of dendrites and neurons. 
Furthermore, in the current study we use a novel clustering tool to aid the analysis of the complex clinical data 
that can find use in future clinical studies to predict the prognosis and outcomes in aMCI subjects. 
Previous studies have similarly attempted to distinguish MCI subtypes and identify clinical and biomarker va-
riables to predict MCI subjects at high risk to convert to dementia. Thus, “multifunctional” and “monofunctional” 
subtypes of amnestic MCI type (aMCI) [30] were separated on the basis of neurocognitive characteristics. The 
multifunctional aMCI type had a more rapid transition to dementia within 5 years of observation compared to 
the monofunctional aMCI; similarly, auditory sensor potentials differ in patients with various aMCI subtypes, 
and these differences are associated with various rates of cognitive decline progression and dementia develop-
ment [4] [37]. 
Cerebrolysin is considered to be an effective therapy directed to prevent further cognitive decline in people 
suffering from dementia, MCI, as well as older people without cognitive impairment [9] [10] [38]-[41]. Howev-
er, the therapeutic effect of cerebrolysin (e.g. halting cognitive decline) especially in MCI subjects, appears not 
to be uniform, with a small number still progressing to overt dementia. This probably reflects the heterogeneity 
of the MCI syndrome that is further confirmed with the poorer neurocognitive profile at baseline [9]. This is not 
surprising and provides further support of mono- and multifunctional subtypes of aMCI being of different bio-
logical origin with different probability of dementia outcome [5]. 
In the present work we have focused on parameter(s), which distinguish patients with distinct response profile 
to cerebrolysin treatment e.g. patients with stable and improved cognitive functioning (favorable subgroup) from 
those with aggravation of their cognitive mental functions (unfavorable treatment outcome). We did not have 
pre-set criteria for “unfavorable” and “favorable” outcomes, and their distinction was a result of extensive clus-
ter analysis recognized as an informative method to classify subjects (patients and/or surveyed individuals) and 
attributes (signs, i.e. neurocognitive and psychometric results, questionnaires, demographic data and results from 
biological studies) from databases, and has been used in both psychiatric and neuropsychological studies [28].  
In the present study, cluster analysis helped distinguish homogenous subgroups of patients following their an-
ti-dementia treatment, taking into account their pre-treatment neuropsychological differences. This novel ap-
proach has enabled us to identify the most informative neurocognitive predictors of unfavorable outcome in 
aMCI subjects treated with cerebrolysin who further progressed to dementia. Furthermore, this analysis was 
successfully based on using the results from neurocognitive tests before the treatment was initiated. However, 
we have to highlight that not all eight patients within this subgroup received the dementia diagnosis (only three 
persons) after three years of treatment. This suggests that there are additional parameters (e.g. biochemical, 
neuroradiological etc.) that influence our model, and they may influence identifying subjects with highest de-
mentia risk among the “risk group”. We also cannot exclude the possibility that subjects in the risk group (“un-
favorable” clusters) could have progressed to dementia if they have been followed longer. 
The linear discriminant analysis (LDA) was helpful to separate the “risk group” (characterized by subsequent 
cognitive decline and unfavorable outcome following treatment) based on test results prior the treatment course. 
This is an important finding, since it can be used to determine the prognosis of the treatment outcomes in future 
clinical trials in aMCI subjects. However, this statistical method cannot be used to rank attributes (signs) and 
decrease the number of tests necessary for the calculation. Longer longitudinal studies on larger patients cohorts 
with inclusion of additional biological attributes (e.g. neuroimaging, CSF biomarkers, EEG etc.), in addition to 
APOE genotyping, would enhance the probability when making projections of dementia development for every 
patient with aMCI and develop differential individual approach to preventive AD therapy with cerebrolysin. 
5. Conclusions 
• The most informative tests used before commencing the treatment with cerebrolysin to predict progressive 
cognitive decline are: MDRS Memory subtest, HDRS, MMSE, Word List Memory Task (10 word list learn-
ing and immediate recall). Lower scores on these tests at baseline, as well as on FAB, and relatively higher 
scores in HDRS argue for unfavorable prognosis for aMCI patients treated with cerebrolysin. 
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• When classifying patients using only their scores before the treatment, there is a reasonable separation of the 
“risk group”, consisting of patients with dementia outcome alongside with those aMCI patients who have si-
milarly lower cognitive scores, but who are not diagnosed with dementia following their 3 years treatment 
with cerebrolysin. When scores from all 17 tests (14 tests before the treatment and three single-measured 
tests) are used, the best group separation using the LDA corresponds to risk group of eight patients (three 
with dementia outcome and five with non-dementia outcome). The value of linear combination of scorings in 
17 tests less than 55 points corresponds to 37.5% probability of dementia outcome. 
• Changes in neurocognitive scores during the treatment course are more informative to identify aMCI patients 
who develop dementia than baseline scores obtained prior starting the treatment, with the most informative 
changes in MMSE, BNT, Digit span forward, and WAIS subtest “Categorical associations” scores. 
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